Videos

Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD

Roundtables

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/14/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the management of patients with HER2-low metastatic breast cancer, sharing data from the DESTINY-Breast06 trial.

In this video, a panel of...

06/14/2024

Oncology

Video

Kayla Monks, MS, RD, on Nutrition for Patients With Liver Disease

06/14/2024

Kayla Monks, MS, RD, discusses nutritional needs and challenges of patients with liver disease, including candidates for transplant, and how to work with patients to achieve the best possible outcomes.

Kayla Monks, MS, RD, discusses...

06/14/2024

Gastroenterology

Conference Coverage

Examining Efficacy and Safety of Novel Armored huCART19-IL18 Treatment for Patients With R/R Lymphoma

06/13/2024

Featuring Jakub Svoboda, MD

Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.

Jakub Svoboda, MD, discusses...

06/13/2024

Oncology

Frederik Marmé, PhD, Heidelberg University

Videos

Atezolizumab Plus Chemotherapy and Bevacizumab Did Not Improve Survival For Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/13/2024

Frederik Marmé, MD, PhD

According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...

According to phase 3 data, the...

06/13/2024

Oncology

Kevin Kalinsky, MD, Winship Cancer Institute

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Video

Laura Raffals, MD, on Top Pearls for Managing Ulcerative Colitis

06/13/2024

Dr Raffals reviews her top pearls for ensuring patients with ulcerative colitis are correctly diagnosed, properly treated and monitored, and benefit from multidisciplinary care.

Dr Raffals reviews her top...

06/13/2024

Advances in Inflammatory Bowel Disease Network

Sponsored

Videos

Foundations of Wound Healing: Exploring Cellular, Acellular, and Matrix Products (Part I)

06/12/2024

The first episode of the June WCW explores cellular, acellular, and matrix products to heal wounds. Join host Dr Jonathan Johnson and guest speaker Dr Naz Wahab as they discuss advances in wound care techniques and dive into differences...

The first episode of the June...

06/12/2024

Wounds

HRS 2024 Conference Coverage

Indications and Risks of Transvenous Lead Extraction: Discussion With Miguel Leal, MD, and Robert Schaller, DO

06/12/2024

Miguel Leal , MD;

Robert Schaller , DO;

Miguel Leal, MD, and Robert Schaller, DO, discuss current and evolving indications of lead extraction, as well as how to establish a relationship with the CT surgical team, prepare for complications, and mitigate risk during high-risk cases.

Miguel Leal, MD, and Robert...

06/12/2024

EP Lab Digest

HRS 2024 Conference Coverage

Highlighting the 2024 HRS Expert Consensus Statement on Arrhythmias in the Athlete: Evaluation, Treatment, and Return to Play

06/11/2024

Interview by Jodie Elrod

In this discussion, Mark Link, MD, and Rachel Lampert, MD, discuss the newly released 2024 HRS expert consensus statement on arrhythmias in the athlete.

In this discussion, Mark Link,...

06/11/2024

EP Lab Digest

Conference Coverage

Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL

06/11/2024

Featuring Matthew Matasar, MD

Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...

Matthew Matasar, MD, discusses...

06/11/2024

Oncology